RGLS : Summary for Regulus Therapeutics Inc. - Yahoo Finance

U.S. Markets open in 20 mins.

Regulus Therapeutics Inc. (RGLS)


NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
1.70+0.30 (+21.43%)
At close: 4:00PM EDT

1.80 0.10 (5.88%)
Pre-Market: 9:03AM EDT

People also watch
PTCTCEMPPTLATGTXVSTM
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close1.40
Open0.00
Bid0.00 x
Ask0.00 x
Day's Range1.45 - 1.75
52 Week Range0.94 - 8.90
Volume3,786,920
Avg. Volume1,030,431
Market Cap89.99M
Beta2.19
PE Ratio (TTM)-1.10
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Regulus to Present at the 16th Annual Needham Healthcare Conference
    PR Newswire41 minutes ago

    Regulus to Present at the 16th Annual Needham Healthcare Conference

    Regulus Therapeutics Inc. (RGLS) is a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs.  Regulus has leveraged its oligonucleotide drug discovery and development expertise to develop a well-balanced microRNA therapeutics pipeline complemented by a rich intellectual property estate to retain its leadership in the microRNA field.  Regulus is advancing several programs in renal, hepatic and central nervous systems diseases, both independently and with our strategic alliance partners, Sanofi and AstraZeneca. Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements associated with the expected ability of Regulus to undertake certain activities and accomplish certain, the projected timeline of clinical development activities, and expectations regarding future therapeutic and commercial potential of Regulus' business plans, technologies and intellectual property related to microRNA therapeutics and biomarkers being discovered and developed by Regulus.  Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements.

  • Business Wire15 hours ago

    SHAREHOLDER ALERT: Goldberg Law PC Announces Securities Class Action Lawsuit Against Regulus Therapeutics Inc. and Encourages Investors With Losses to Contact the Firm

    Goldberg Law PC, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Regulus Therapeutics Inc. .

  • Accesswireyesterday

    Increased Volume Spurs Stock Prices of Benitec Biopharma, Regulus Therapeutics

    NEW YORK, NY / ACCESSWIRE / March 27, 2017 / Higher volumes were the order of the day for these two biotech stocks, as each stock saw a double digit percent increase in the price of their stocks. Regulus ...